Singapore: Proteus Digital Health and Otsuka Pharmaceutical, a subsidiary of Japan-headquartered Otsuka Group, have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines. These new medicines will be based on Otsuka's pharmaceutical products and Proteus's digital health feedback system incorporating Proteus's novel sensor-based technologies.

Under the agreement, Proteus and Otsuka will exclusively collaborate to develop commercial products in two defined therapeutic areas of high unmet medical need. Otsuka has also been granted a non-exclusive license to utilize Proteus technology in its clinical research and development activities. Financial terms of the agreement were not disclosed.